Healthcare Global Enterprises Announces Q4 and Full-Year Financial Results for FY26
Healthcare Global Enterprises Limited (HCG), India's largest dedicated cancer hospital network, has announced its financial results for the quarter and full year ended March 31, 2026. The company's performance reflects consistent execution across its network, supported by resilient demand for high-quality oncology care.HCG reported strong consolidated results for the quarter and full fiscal year, detailing key financial metrics across revenues, EBITDA, and profit.
Financial Highlights (Consolidated)
The financial data highlights the growth trends for the period:| Particulars (Rs. Mn.) | Q4FY26 | Q4FY25 | YoY | FY26 | FY25 | YoY |
|---|---|---|---|---|---|---|
| Revenue from Operations | 6523 | 5852 | 11% | 25454 | 22228 | 15% |
| Adjusted EBITDA 1 | 1252 | 1070 | 17% | 4711 | 3963 | 19% |
| Margin (%) | 19.2 | 18.3 | +91 bps | 18.5 | 17.8 | +68 bps |
| Adjusted PAT 2 | 341 | 74 | 363% | 557 | 444 | 25% |
Operational Performance and Outlook
Commenting on the results, Dr. Manish Mattoo, CEO of HealthCare Global Enterprises Ltd., stated that the full year performance demonstrated consistent execution across the network. For the full year, revenues grew by 15% to Rs. 25,454 mn.The company's operating performance remained well-balanced across regional clusters, driven by demand for high-quality oncology care across medical, radiation, and surgical modalities. Adjusted EBITDA for FY26 grew by 19% to Rs. 4,711 mn, while margins stood at 18.5%.
This strong momentum was sustained in Q4 FY26, where adjusted EBITDA increased by 17% to Rs. 1,252 mn, and margins expanded to 19.2%.
A key milestone during the reporting period was the successful completion of a Rs. 4,250 mn rights issue. This capital infusion strengthened the financial foundation, providing greater flexibility for investments in long-term priorities, including capacity expansion, clinical infrastructure upgrades, and technology investments.
Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, emphasized that cancer care must move beyond treatment to include early diagnosis, precision, continuity of care, and improving quality of life. He highlighted that HCG's strength lies in its ability to integrate specialists, advanced diagnostics, research, and personalized treatment pathways under one platform.
Looking ahead, HCG remains focused on strengthening next-generation oncology capabilities, including precision medicine, molecular diagnostics, genomics, robotics, and data-driven clinical decision-making. The company's purpose remains clear: to make high-quality, affordable, and patient-centric cancer care accessible to millions across India.
HealthCare Global Enterprises Ltd. (HCG) is the largest provider of cancer care in India. Through its network of 25 hospitals across India and Africa, HCG provides advanced cancer care, offering comprehensive centers for the diagnosis and treatment of cancer under one roof.
HCG Stock Price Movement
On Tuesday, Healthcare Global Enterprises Limited shares edged higher, gaining 2.73% to close at ₹646.85. The stock saw robust trading activity, with 132,428 shares transacted during the session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: